^
    Back
    Association details:
    Biomarker:BRAF G469R
    Cancer:Non Small Cell Lung Cancer
    Drug:sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    Anticancer Drugs
    Title:

    A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation

    Excerpt:
    ...a case report of a patient with NSCLC and the BRAF G469R mutation who showed a dramatic response to sorafenib.
    DOI:
    10.1097/CAD.0000000000000277